The CLEVER Study - Coreg And Left Ventricular Mass Regression
Public ClinicalTrials.gov record NCT00108082. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination With and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients With Left Ventricular Hypertrophy (LVH).
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to compare the effects of COREG MR (carvedilol modified release formulation) to atenolol on indices of left ventricular dimensions when added to standardized angiotensin converting enzyme (ACE) inhibition, and to the effect of ACE inhibition alone. Subjects with LVH (left ventricular hypertrophy) and hypertension will be studied. The primary endpoint will be the change in left ventricular mass index (LVMI) characterized by magnetic resonance imaging (MRI) following 12 months of treatment. Secondary endpoints include the change in LV (left ventricular) mass, LV wall thickness, diastolic left ventricular filling parameters, and left ventricular ejection fraction by echocardiographic methods at Treatment Month 12. Composite outcomes and individual event data will also be evaluated by treatment group.
Study identification
- NCT ID
- NCT00108082
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 287 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2005 (Type not available)
- Primary completion
- Aug 2008 (Actual)
- Completion
- Aug 2008 (Actual)
- Last update posted
- Dec 16, 2016
2005 – 2008
United States locations
- U.S. sites
- 78
- U.S. states
- 26
- U.S. cities
- 68
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Birmingham | Alabama | 35235 | — |
| GSK Investigational Site | Birmingham | Alabama | 35249 | — |
| GSK Investigational Site | Mobile | Alabama | 36608 | — |
| GSK Investigational Site | Chandler | Arizona | 77030 | — |
| GSK Investigational Site | Mesa | Arizona | 85206 | — |
| GSK Investigational Site | Peoria | Arizona | 85381 - 4828 | — |
| GSK Investigational Site | Scottsdale | Arizona | 85251 | — |
| GSK Investigational Site | Scottsdale | Arizona | 85260 | — |
| GSK Investigational Site | Sun City | Arizona | 85351 | — |
| GSK Investigational Site | Fresno | California | 93720 | — |
| GSK Investigational Site | Los Angeles | California | 90033 | — |
| GSK Investigational Site | Los Angeles | California | 90048 | — |
| GSK Investigational Site | Los Angeles | California | 90095 | — |
| GSK Investigational Site | Palo Alto | California | 94301 | — |
| GSK Investigational Site | Poway | California | 92064 | — |
| GSK Investigational Site | Sacremento | California | 95819 | — |
| GSK Investigational Site | San Diego | California | 92120 | — |
| GSK Investigational Site | San Leandro | California | 94578 | — |
| GSK Investigational Site | Santa Ana | California | 92705 | — |
| GSK Investigational Site | Colorado Springs | Colorado | 80907 | — |
| GSK Investigational Site | Colorado Springs | Colorado | 80919 | — |
| GSK Investigational Site | Denver | Colorado | 80204 | — |
| GSK Investigational Site | Denver | Colorado | 80218 | — |
| GSK Investigational Site | Newark | Delaware | 19718 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20037 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20422 | — |
| GSK Investigational Site | Altamonte Springs | Florida | 32714 | — |
| GSK Investigational Site | Atlantis | Florida | 33462 | — |
| GSK Investigational Site | Jacksonville | Florida | 32209 | — |
| GSK Investigational Site | Kissimmee | Florida | 34741 | — |
| GSK Investigational Site | Longwood | Florida | 32779 | — |
| GSK Investigational Site | Miami | Florida | 33156 | — |
| GSK Investigational Site | Ormond Beach | Florida | 32714 | — |
| GSK Investigational Site | Pembroke Pines | Florida | 33029 | — |
| GSK Investigational Site | Evanston | Illinois | 60201 | — |
| GSK Investigational Site | Vernon Hills | Illinois | 60061 | — |
| GSK Investigational Site | Fort Wayne | Indiana | 46804 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46202 | — |
| GSK Investigational Site | Scarborough | Maine | 04074 | — |
| GSK Investigational Site | Baltimore | Maryland | 21224 | — |
| GSK Investigational Site | Columbia | Maryland | 21044 | — |
| GSK Investigational Site | Pikesville | Maryland | 21215 | — |
| GSK Investigational Site | Grand Rapids | Michigan | 49525 | — |
| GSK Investigational Site | Edina | Minnesota | 55435 | — |
| GSK Investigational Site | Minneapolis | Minnesota | 55417 | — |
| GSK Investigational Site | Camden | New Jersey | 08103 | — |
| GSK Investigational Site | Buffalo | New York | 14215 | — |
| GSK Investigational Site | New York | New York | 10011 | — |
| GSK Investigational Site | New York | New York | 10021 | — |
| GSK Investigational Site | New York | New York | 10128 | — |
| GSK Investigational Site | Williamsville | New York | 14221 | — |
| GSK Investigational Site | Fayetteville | North Carolina | 28304 | — |
| GSK Investigational Site | Greensboro | North Carolina | 27401 | — |
| GSK Investigational Site | Winston-Salem | North Carolina | 27157 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45224 | — |
| GSK Investigational Site | Cincinnati | Ohio | 45267 | — |
| GSK Investigational Site | Cleveland | Ohio | 44122 | — |
| GSK Investigational Site | Hillsboro | Oregon | 97123-4117 | — |
| GSK Investigational Site | Portland | Oregon | 97210 | — |
| GSK Investigational Site | Allentown | Pennsylvania | 18105 | — |
| GSK Investigational Site | Camp Hill | Pennsylvania | 17011 | — |
| GSK Investigational Site | Doylestown | Pennsylvania | 18901 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19140 | — |
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15212 | — |
| GSK Investigational Site | West Grove | Pennsylvania | 19390 | — |
| GSK Investigational Site | Warwick | Rhode Island | 02886 | — |
| GSK Investigational Site | Columbia | South Carolina | 29204 | — |
| GSK Investigational Site | Greenville | South Carolina | 29615 | — |
| GSK Investigational Site | Greer | South Carolina | 29651 | — |
| GSK Investigational Site | Kingsport | Tennessee | 37660 | — |
| GSK Investigational Site | Knoxville | Tennessee | 37920 | — |
| GSK Investigational Site | Nashville | Tennessee | 37205 | — |
| GSK Investigational Site | Houston | Texas | 77030 | — |
| GSK Investigational Site | Danville | Virginia | 24541 | — |
| GSK Investigational Site | Roanoke | Virginia | 24014 | — |
| GSK Investigational Site | Springfield | Virginia | 22151 | — |
| GSK Investigational Site | Tacoma | Washington | 98405 | — |
| GSK Investigational Site | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00108082, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2016 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00108082 live on ClinicalTrials.gov.